Preliminary evaluation of safety of conditionally replication adenovirus M4

Abstract

Conditionally replication adenovirus M4, which was constructed in our lab, was proved to have good clinical application prospect for its good anti-tumor and anti-metastasis effect. However, clinically applying M4 faces many problems. One of the most important is the safety of M4. In this study, we investigated the safety of M4 by comparing with Adv-TK, which was proved to be safe in I–III phase clinical trials. M4 and Adv-TK were injected into mice via the tail vein separately, and the mice were sacrificed at the indicated time. Blood was collected for biochemical tests, the liver was harvested for hematoxylin and eosin (H&E) staining and viral quantification, and splenic lymphocytes were separated for adenovirus specific cellular immune response. Our results showed that M4 had no obvious effect on mouse general symptoms. A transient reversible infiltration of inflammatory cells in collect abbacy was only observed in M4 group, and a transient slight increase in Cr level was detected both after M4 and Adv-TK injection. The adenovirus specific cellular immune response induced by M4 was similar to that by Adv-TK, and the distribution and metabolism of M4 in the mouse liver were also similar to those of Adv-TK. It was concluded that conditionally replication adenovirus M4 had the same safety as Adv-TK. The study provides safety basis for the coming clinical trials of M4.

References

[1] MizuguchiH., HayakawaT.. Targeted adenovirus vectors. Hum Gene Ther, 2004, 15(11): 1034-1044

[2] EmunaitisJ., GanlyI., KhuriF., et al.. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res, 2000, 60(22): 6359-6366

[3] DeWeeseT.L., van der PoelH., LiS., et al.. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res, 2001, 61(20): 7464-7472

[4] FreytagS.O., StrickerH., PeggJ., et al.. Phase I study of replication-competent adenovirus-mediated double- suicide gene therapy in combination with conventional- dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res, 2003, 63(21): 7497-7506

[5] PageJ.G., TianB., SchweikartK., et al.. Identifying the safety profile of a novel infectivity-enhanced conditionally replicative adenovirus, Ad5-delta24-RGD, in anticipation of a phase I trial for recurrent ovarian cancer. Am J Obstet Gynecol, 2007, 196(4): 389

[6] HanZ., HongZ., ChenC., et al.. A novel oncolytic adenovirus selectively silences the expression of tumor-associated STAT3 and exhibits potent antitumoral activity. Carcinogenesis, 2009, 30(12): 2014-2022

[7] LiN., ZhouJ., WengD., et al.. Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma. Clin Cancer Res, 2007, 13(19): 5847-5854

[8] ThackerE.E., TimaresL., MatthewsQ.L.. Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccines, 2009, 8(6): 761-77

[9] PalmerD.H., MautnerV., KerrD.J.. Clinical experience with adenovirus in cancer therapy. Curr Opin Mol Ther, 2002, 4(5): 423-434

[10] VarnavskiA.N., CalcedoR., BoveM., et al.. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naive and preimmunized mice. Gene Ther, 2005, 12(5): 427-436

[11] MakowerD., RozenblitA., KaufmanH., et al.. Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin Cancer Res, 2003, 9(2): 693-702

[12] LuW., ZhengS., LiX.F., et al.. Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial. World J Gastroenterol, 2004, 10(24): 3634-3638

[13] SuC., CaoH., TanS., et al.. Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates. Toxicol Sci, 2008, 106(1): 242-250

[14] PageC., HuangM., JinX., et al.. Elevated phosphorylation of AKT and STAT3 in prostate, breast, and cervical cancer cells. Int J Oncol, 2000, 17(1): 23-28

[15] MoraL.B., BuettnerR., SeigneJ., et al.. Constitutive activation of STAT3 in human prostate tumors and cell lines: direct inhibition of STAT3 signaling induces apoptosis of prostate cancer cells. Cancer Res, 2002, 62(22): 6659-6666

[16] KusabaT., NakayamaT., YamazumiK., et al.. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol, 2005, 58(8): 833-838

[17] RosenD.G., Mercado-UribeI., YangG., et al.. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer, 2006, 107(11): 2730-2740

[18] TurksonJ.. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets, 2004, 8(5): 409-422

[19] TurksonJ., JoveR.. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene, 2000, 19(56): 6613-6626

[20] YuH., JoveR.. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer, 2004, 4(2): 97-105

[21] Al Zaid SiddiqueeK., TurksonJ.. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res, 2008, 18(2): 254-267

[22] SantosF.P., KantarjianH.M., JainN., et al.. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood, 2010, 115(6): 1131-1136

[23] VerstovsekS., KantarjianH., MesaR.A., et al.. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med, 2010, 363(12): 1117-1127

[24] ZaissA.K., MachadoH.B., HerschmanH.R.. The influence of innate and pre-existing immunity on adenovirus therapy. J Cell Biochem, 2009, 108(4): 778-790

RIGHTS & PERMISSIONS

Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg